Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1301-1310 Newer>

The Motley Fool July 13, 2004 Brian Gorman	The "Cialis Promise" Eli Lilly and Icos are offering a free trial of their drug Cialis for men who have never used it before and promise that participants not pleased with the results will receive a voucher for a competing product.
HBS Working Knowledge July 12, 2004 Porter & Teisberg	Michael Porter's Prescription for the High Cost of Health Care The troubled U.S. health care system needs a brave, new kind of competition, say the authors of this Harvard Business Review excerpt.
The Motley Fool July 12, 2004 Brian Gorman	India Woos U.S. Biotech Companies Business abroad would bode well for investors and consumers.
The Motley Fool July 12, 2004 Ben McClure	Falling for Amgen Ahead of its second-quarter earnings release, the biotech giant looks good.
The Motley Fool July 9, 2004 Phil Wohl	Abbott Labs Concocts Strong Q2 The drug maker reports earnings as expected and refines its third-quarter guidance.
The Motley Fool July 9, 2004 Charly Travers	Protein Design Labs' Windfall Royalties from Genentech could mean big things for PDL.
The Motley Fool July 8, 2004 W.D. Crotty	From Flameout to Bargain Despite its stock decline, there's a lot to like about French biopharmaceutical Flamel.
The Motley Fool July 8, 2004 Charly Travers	Genentech's Next Billion-Dollar Drug The cancer drug Avastin looks like a big winner. The market had exceptionally high expectations for this product, and it certainly seems well on its way to becoming a blockbuster drug.
ifeminists July 7, 2004 Diana Goss	An Investigation Into the Prescribing of Drugs for Non-Medical Concerns In the light of new drugs being developed to resolve so-called "female sexual dysfunctions," it has now been clearly identified that female sexuality has been genderised by the way in which those who are analysing it would prefer us all to view this.
The Motley Fool July 7, 2004 Brian Gorman	Acusphere Makes a Friend The small firm announced that it sealed a $70 million partnership for AI-700, its experimental ultrasound contrast agent, with privately held European pharmaceutical concern Nycomed. Shares of Acusphere soared 20% on news of the pact.
<Older 1301-1310 Newer> Return to current articles.